Hookipa Pharma (NASDAQ:HOOK – Free Report) had its price target increased by JMP Securities from $23.00 to $24.00 in a report released on Friday morning, Benzinga reports. They currently have a market outperform rating on the stock.
HOOK has been the topic of several other research reports. HC Wainwright boosted their price objective on Hookipa Pharma from $50.00 to $60.00 and gave the stock a buy rating in a report on Wednesday, June 5th. Royal Bank of Canada restated an outperform rating and set a $50.00 price target on shares of Hookipa Pharma in a report on Tuesday, May 21st.
View Our Latest Stock Analysis on Hookipa Pharma
Hookipa Pharma Stock Performance
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.44) by ($0.08). The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $5.68 million. Hookipa Pharma had a negative return on equity of 33.33% and a negative net margin of 88.73%. On average, sell-side analysts expect that Hookipa Pharma will post -2.57 EPS for the current fiscal year.
Institutional Investors Weigh In On Hookipa Pharma
A number of institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC lifted its position in shares of Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after purchasing an additional 83,800 shares in the last quarter. Acadian Asset Management LLC increased its stake in Hookipa Pharma by 12.3% in the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after buying an additional 108,844 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Hookipa Pharma in the 1st quarter worth approximately $31,000. 63.88% of the stock is currently owned by institutional investors and hedge funds.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Featured Articles
- Five stocks we like better than Hookipa Pharma
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- How to Invest in Silver: A Beginner’s Guide
- How to Use the MarketBeat Excel Dividend Calculator
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.